title: Association between LDL-C, Non HDL-C, and Apolipoprotein B Levels with Coronary Plaque Regression.
abstract: BACKGROUND
  Previous reports have inferred a linear relationship between LDL-C and changes in coronary plaque volume (CPV) measured by intravascular ultrasound. However, these publications included a small number of studies and did not explore other lipid markers.
  
  
  OBJECTIVE
  To assess the association between changes in lipid markers and regression of CPV using published data.
  
  
  METHODS
  We collected data from the control, placebo and intervention arms in studies that compared the effect of lipidlowering treatments on CPV, and from the placebo and control arms in studies that tested drugs that did not affect lipids. Baseline and final measurements of plaque volume, expressed in mm3, were extracted and the percentage changes after the interventions were calculated. Performing three linear regression analyses, we assessed the relationship between percentage and absolute changes in lipid markers and percentage variations in CPV.
  
  
  RESULTS
  Twenty-seven studies were selected. Correlations between percentage changes in LDL-C, non-HDL-C, and apolipoprotein B (ApoB) and percentage changes in CPV were moderate (r = 0.48, r = 0.47, and r = 0.44, respectively). Correlations between absolute differences in LDL-C, non‑HDL-C, and ApoB with percentage differences in CPV were stronger (r = 0.57, r = 0.52, and r = 0.79). The linear regression model showed a statistically significant association between a reduction in lipid markers and regression of plaque volume.
  
  
  CONCLUSIONS
  A significant association between changes in different atherogenic particles and regression of CPV was observed. The absolute reduction in ApoB showed the strongest correlation with coronary plaque regression.
authors.affiliation: Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, AR.
authors.forename: Walter
authors.initials: W
authors.lastname: Masson
authors.affiliation: Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, AR.
authors.forename: Daniel
authors.initials: D
authors.lastname: Siniawski
authors.affiliation: Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, AR.
authors.forename: Martín
authors.initials: M
authors.lastname: Lobo
authors.affiliation: Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, AR.
authors.forename: Graciela
authors.initials: G
authors.lastname: Molinero
authors.affiliation: Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, AR.
authors.forename: Mariano
authors.initials: M
authors.lastname: Giorgi
authors.affiliation: Consejo de Epidemiología y Prevención Cardiovascular, Sociedad Argentina de Cardiología, Buenos Aires, AR.
authors.forename: Melina
authors.initials: M
authors.lastname: Huerín
mesh_terms: D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001055:Apolipoproteins B / Q000097:blood*; D001132:Arm; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003324:Coronary Artery Disease / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D058226:Plaque, Atherosclerotic / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy; D012016:Reference Values; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D000924:Anticholesteremic Agents; D001055:Apolipoproteins B; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL